Bone Biologics Files Patent Application for Breakthrough Bone Regeneration Technology
DENVER, Colo., Jun 27, 2025 (247marketnews.com)- Bone Biologics (NASDAQ:BBLG) filed a new patent application with the United States Patent and Trademark Office (USPTO) related to its proprietary NELL-1 protein technology.
The application covers recombinant human NELL-1 (rhNELL-1) polypeptide compositions and their use in treating bone-related conditions, including applications in spinal fusion, trauma, and osteoporosis. If granted, this patent will expand and strengthen the company’s intellectual property portfolio, reinforcing its position at the forefront of next-generation bone regeneration.
Jeffrey Frelick, CEO of Bone Biologics, stated, “This patent application marks a major milestone in our mission to bring effective treatments to spine fusion patients.”
Additionally, yesterday Bone Biologics also announced that received formal notice from Nasdaq confirming that it regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2).
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (BBLG)
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/04/25 09:00 AM
- Biotech, Dividends & New Deals: Market Movers Lighting Up the Pre-Market Tape
- MoBot’s Stock Market Highlights – 09/04/25 08:00 AM
- MoBot alert highlights: NASDAQ: HWH, NASDAQ: BBLG, NASDAQ: PPBT, NASDAQ: ZNB, NASDAQ: NCI (09/04/25 07:00 AM)
- 24/7 Market News Snapshot 04 September, 2025 – Bone Biologics Corp Common Stock (NASDAQ:BBLG)